Finding solutions to the world’s toughest challenges is the mission of AbbVie, a research-based, pharmaceutical company. Curing brain cancer falls into the category of one of the toughest challenges in oncology today, according to the company.
AbbVie is a partner with the American Brain Tumor Association as it works to find ways to support the patient community.
“We are inspired by the American Brain Tumor Association’s dedication to those impacted by brain tumors, its education about brain tumors, and overall research efforts,” says the company.
“As we expand our efforts, including research and potential treatments for brain tumors, our work with the ABTA remains valuable in helping us understand how we can best support brain tumor patients and their families and reinforce our commitment to this important area of research.”
The company was founded in 2013, at which time it became a separate company from Abbott Laboratories. It works to find solutions in the areas of immunology, oncology, neuroscience and virology. Part of its mission is to develop medicines that improve treatment by combining knowledge of biology with cutting-edge technologies. AbbVie says it works closely with scientists, clinical experts, industry peers, advocates and patients.
Its team of oncology experts is working to transform the way cancer is treated and to develop and deliver breakthroughs for patients. The company says it is leveraging expertise in blood cancer for novel research in some of the most difficult-to-treat tumors, including brain tumors.
According to the AbbVie website, the company’s medications treat 30 different medical conditions; it employs 30,000 worldwide, it treats 26 million patients worldwide with various Abbvie medications and it invested $4.8 billion in advancing science in 2017. Richard Gonzalez is the CEO and chairman. The company is headquartered in North Chicago.
In our 45 years, the most dramatic advances are being made now.
Let’s put our brains together to stop brain tumors once and for all. Your donation makes a difference.